Jair Bar

21PUBLICATIONS
160CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersChemotherapyLiquid biopsies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (21)

|Jun 29, 2026
Author Correction: SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial.

|Jun 01, 2026
SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial.

|May 01, 2026
Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors.

|Nov 19, 2025
Prevalence, molecular characterization, and prognosis of c-Met protein overexpression in a real-world cohort of patients with non-squamous non-small cell lung cancer.

Jair Bar, Mona H Cai, Yookyung Christy Choi

|Aug 12, 2025
Real-World Response and Survival Outcomes and Treatment Patterns in Patients With Extensive Stage Small-Cell Lung Cancer Receiving Third-Line Treatment.

Jair Bar, Qingqing Xu, Sudeep Karve

|Jul 17, 2025
Personalized care for patients with EGFR-mutant nonsmall cell lung cancer: Navigating early to advanced disease management.

Maxime Borgeaud, Timothée Olivier, Jair Bar

Pageof 4

Frequent Collaborators

3 joint publications

Iris Kamer

3 joint publications

Ji-Youn Han

3 joint publications

Lauren Averett Byers

2 joint publications

Anne C Chiang